近日，南京融捷康生物(wù)科(kē)技(jì )有(yǒu)限公(gōng)司发布的一则招募中(zhōng)重度哮喘患者的消息引人关注。原来，由融捷康自研的國(guó)内首个自免双特异性纳米抗體(tǐ)药物(wù)——RC1416注射液，正在全國(guó)数十家知名(míng)医(yī)院开展临床研究。这款双抗药品在药效、安(ān)全性和成药性等多(duō)重指标上具(jù)有(yǒu)较好的优势，未来有(yǒu)望成為(wèi)中(zhōng)重度哮喘患者的福音。

RC1416 injection, developed by Nanjing RegeneCore Biotech Co.,Ltd, is currently undergoing a Phase Ib clinical study to "evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary effectiveness of RC1416 injection in patients with moderate to severe asthma." The lead institution for this study is the China-Japan Friendship Hospital in Beijing, and it is simultaneously being conducted at dozens of renowned hospitals across the country.

Regenecore used own nanobody platform to screen and construct bispecific nanobodies targeting IL-4Rα and IL-5.